Compare AbCellera Biologics Inc (ABCL) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Alphabet Inc Class A — how do they compare? AbCellera Biologics Inc trades at $10.83 (market cap $3.17B), while Alphabet Inc Class A trades at $346.16 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 1324.9× AbCellera Biologics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GOOGL | |
|---|---|---|
Market Cap | $3.17B | $4.20T |
Sector | Health | Media |
52-Week High | $10.36 | $402.62 |
52-Week Low | $2.78 | $199.32 |
Enterprise Value | $2.77B | $4.08T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
Alphabet (GOOGL) trades at $345.63, up 0.53% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and robust profitability margins support growth, while analyst consensus remains overwhelmingly bullish. Key developments include AI partnerships and YouTube subscription price increases, signaling strategic expansion amid competitive pressures.
Outlook is positive driven by AI innovation and earnings momentum, though regulatory risks and market volatility pose challenges. The stock offers long-term value with a consensus price target of $426.28, representing significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
